Neonatal seizures are the most common neurological emergency, and neonatal status epilepticus (NSE) remains a controversial entity, with no general consensus about its definition and treatment. Here, we report on three newborns with NSE refractory to first- and second-line antiepileptic drugs successfully treated with intravenous (IV) hydrocortisone. The patients had previously failed therapy with levetiracetam, phenobarbital and midazolam, showing persistent clinical and electrical seizures. Modulation of brain inflammation triggered during prolonged epileptic activity has been thought to potentially explain the beneficial effects of anti-inflammatory treatment.
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases
Di Rosa, Gabriella
Primo
Writing – Review & Editing
;Dicanio, DanielaWriting – Original Draft Preparation
;Nicotera, Antonio GennaroWriting – Original Draft Preparation
;Mondello, Patrizia;Cannavò, Laura;Gitto, EloisaUltimo
2020-01-01
Abstract
Neonatal seizures are the most common neurological emergency, and neonatal status epilepticus (NSE) remains a controversial entity, with no general consensus about its definition and treatment. Here, we report on three newborns with NSE refractory to first- and second-line antiepileptic drugs successfully treated with intravenous (IV) hydrocortisone. The patients had previously failed therapy with levetiracetam, phenobarbital and midazolam, showing persistent clinical and electrical seizures. Modulation of brain inflammation triggered during prolonged epileptic activity has been thought to potentially explain the beneficial effects of anti-inflammatory treatment.File | Dimensione | Formato | |
---|---|---|---|
Flebocortid 2020.pdf
accesso aperto
Descrizione: manoscritto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
6.49 MB
Formato
Adobe PDF
|
6.49 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.